This clinical trial is focused on studying a kidney disease called Focal Segmental Glomerulosclerosis (FSGS). FSGS is a condition that affects the kidney’s filtering units, leading to scarring and potential kidney damage. The study is testing a treatment called DMX-200, which is a capsule containing the active substance Repagermanium. This treatment is being evaluated for its effectiveness and safety in patients who are already receiving a type of medication known as an Angiotensin II Receptor Blocker (ARB). ARBs are commonly used to manage high blood pressure and protect the kidneys.

The purpose of the study is to assess how well DMX-200 works in improving kidney function and its safety over time. Participants in the study will be randomly assigned to receive either DMX-200 or a placebo, which looks like the treatment but does not contain the active substance. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual treatment or the placebo, ensuring unbiased results. The treatment period will last for several months, during which participants will have regular check-ups to monitor their kidney function and overall health.

In addition to DMX-200, the study involves several ARBs, including Losartan, Candesartan, Telmisartan, Irbesartan, Valsartan, Azilsartan Medoxomil, and Olmesartan Medoxomil. These medications are taken orally and are part of the standard treatment for managing FSGS. The study aims to provide valuable information on the potential benefits of adding DMX-200 to the existing treatment regimen for patients with FSGS.